



US009545412B2

(12) **United States Patent**  
**Cau et al.**

(10) **Patent No.:** US 9,545,412 B2  
(45) **Date of Patent:** Jan. 17, 2017

(54) **COMPOSITION AND METHODS USED DURING ANTI-HIV TREATMENT**(71) Applicant: **UNIVERSITE D'AIX-MARSEILLE**, Marseilles (FR)(72) Inventors: **Pierre Cau**, Puyricard (FR); **Nicolas Levy**, Marseilles (FR)(73) Assignee: **UNIVERSITE D'AIX-MARSEILLE**, Marseille (FR)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/733,725**(22) Filed: **Jun. 8, 2015**(65) **Prior Publication Data**

US 2015/0342970 A1 Dec. 3, 2015

**Related U.S. Application Data**

(63) Continuation of application No. 12/811,474, filed as application No. PCT/FR2008/001844 on Dec. 31, 2008, now abandoned.

(Continued)

(51) **Int. Cl.****A01N 37/36** (2006.01)  
**A61K 31/66** (2006.01)

(Continued)

(52) **U.S. Cl.**CPC ..... **A61K 31/675** (2013.01); **A61K 31/215** (2013.01); **A61K 31/22** (2013.01); **A61K 45/06** (2013.01);

(Continued)

(58) **Field of Classification Search**CPC .. **A61K 31/675; A61K 31/66; A61K 31/4025; A61K 31/366; A61K 31/22; A61K 31/427; A61K 31/665**

(Continued)

(56) **References Cited**

## U.S. PATENT DOCUMENTS

5,652,227 A 7/1997 Teronen et al.  
5,733,558 A 3/1998 Breton et al.

(Continued)

## FOREIGN PATENT DOCUMENTS

EP 1 127 573 A1 8/2001  
EP 1 566 177 A1 8/2005

(Continued)


## OTHER PUBLICATIONS

Martinez et al. "Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy," Antiviral Therapy, 2004, vol. 9, pp. 649-663.\*

(Continued)

*Primary Examiner* — Shengjun Wang(74) *Attorney, Agent, or Firm* — Arent Fox LLP(57) **ABSTRACT**

This invention relates to a composition comprising an anti-HIV treatment and a treatment for side effects of said anti-HIV treatment in an HIV-infected patient. This invention is, for example, very useful in the treatment of side effects caused by certain anti-HIV treatments, for example premature aging and lipodystrophy, which can be caused by protease inhibitors or reverse transcriptase inhibitors. The composition of this invention includes at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, at least one farnesyl-pyrophosphate synthase inhibitor, and at least one anti-HIV agent. One of the processes for treating an HIV-infected patient includes, in any order, the following steps: (i) administration of a mixture including at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and at least one farnesyl-pyrophosphate synthase inhibitor and (ii) administration of an anti-HIV agent, in which the administrations are concomitant, successive or alternative.

**15 Claims, 16 Drawing Sheets****GAPD**

**Related U.S. Application Data**

(60) Provisional application No. 61/018,688, filed on Jan. 3, 2008.

**(51) Int. Cl.**

*A61K 31/675* (2006.01)  
*A61K 31/497* (2006.01)  
*C07D 239/42* (2006.01)  
*A61K 31/505* (2006.01)  
*A61K 31/44* (2006.01)  
*A61K 31/425* (2006.01)  
*A61K 31/34* (2006.01)  
*A61K 31/215* (2006.01)  
*A61K 31/22* (2006.01)  
*A61K 45/06* (2006.01)  
*A61K 31/427* (2006.01)  
*A61K 31/496* (2006.01)  
*A61K 31/366* (2006.01)  
*A61K 31/4025* (2006.01)  
*A61K 31/665* (2006.01)

**(52) U.S. Cl.**

CPC ..... *A61K 31/366* (2013.01); *A61K 31/4025* (2013.01); *A61K 31/427* (2013.01); *A61K 31/496* (2013.01); *A61K 31/66* (2013.01); *A61K 31/665* (2013.01)

**(58) Field of Classification Search**

USPC ..... 514/163, 94, 75, 274, 423  
 See application file for complete search history.

**(56) References Cited****U.S. PATENT DOCUMENTS**

5,902,805 A	5/1999	Breton et al.
8,518,914 B2 *	8/2013	Levy ..... A61K 31/22 514/108
9,072,757 B2 *	7/2015	Levy ..... A61K 31/22
2001/0036936 A1	11/2001	Day et al.
2003/0105121 A1	6/2003	Bihari
2005/0020517 A1	1/2005	Drees et al.
2006/0078531 A1	4/2006	Sota
2006/0275294 A1	12/2006	Omoigui
2010/0120720 A1	5/2010	Levy et al.

**FOREIGN PATENT DOCUMENTS**

WO	WO 02/00168 A2	1/2002
WO	WO 2004/024165 A1	3/2004
WO	WO 2004/050077 A1	6/2004
WO	WO 2005/021001 A1	3/2005
WO	WO 2005/074916 *	8/2005
WO	WO 2005/074916 A1	8/2005
WO	WO 2009/112653 A2	9/2009

**OTHER PUBLICATIONS**

- Kravcik "Update on HIV lipodystrophy," *HIV Clin. Trials*, 2004, vol. 5, No. 3, pp. 152-167.\*  
 Brown et al. "Osteopenia and Osteoporosis in Patient with HIV: review of current concepts," *Current Infectious Disease Reports*, Mar. 2006, vol. 8, No. 2, pp. 162-170.\*  
 Gordon, et al., "Reduced Adiponectin and HDL Cholesterol without Elevated C-Reactive Protein: Clues to the Biology of Premature Atherosclerosis in Hutchinson-Gilford Progeria Syndrome", *J. Pediatrics*, 2005, 146(3): 336-341.  
 Fong, et al., "A Protein Farnesyltransferase Inhibitor Ameliorates Disease in a Mouse Model of Progeria", *Science*, 2006, 311: 1621-1623.  
 Toth, et al., "Blocking Protein Farnesyltransferase Improves Nuclear Shape in Fibroblasts from Humans with Progeroid Syndromes", *PNAS*, 2005, 102(36): 12873-12878.

van Beek, et al., "Farnesyl Pyrophosphate Synthase is the Molecular Target of Nitrogen-Containing Bisphosphonates", *Biochemical and Biophysical Research Communications*, 1999, 264, 108-111.

Leslie B. Gordon , et al., Clinical Trial of a Farnesyltransferase Inhibitor in Children with Hutchinson-Gilford Progeria Syndrome, Oct. 9, 2012, vol. 109, No. 41, pp. 16666-16671, *PNAS*.

U.S. Appl. No. 12/811,622, filed Mar. 16, 2011.

Merideth, M.A., et al. "Phenotype and course of Hutchinson-Gilford progeria syndrome", *N. Engl. J. Med.*, 358: 592-604 (2008).

Gerhard-Herman, M., et al. "Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome", *Hypertension* 59: 92-97 (2012) (with online supplement pp. 1-5).

Ali, K. Mandy, et al., "Cardiovascular disease risk reduction by raising HDL cholesterol-current therapies and future opportunities", *Br. J. Pharmacol.* 167: 1177-1194 (2012).

Wright, R.S. "Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol," *Curr. Opin. Cardiol.* 28: 389-398 (2013).

Olive, M., et al. "Cardiovascular pathology in Hutchinson-Gilford progeria; correlation with the vascular pathology of aging", *Arterioscler Thromb. Vasc. Biol.*, 30: 2301-2309 (2010) (supplemental material—17 pages).

Gu, W., et al., "A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies", *Anticancer Drugs*, 16(10): 1059-1069 (2005).

O'Gorman, D.S., et al., "Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health; a review of the risks and benefits", *Vasc. Health Risk Manag.* 7: 1-14 (2011).

ClinicalTrial.gov, for NCT00425607, "Phase II Trial of Lonafarnib (A Farnesyltransferase Inhibitor) for Progeria", Last update: Dec. 24, 2007, pp. 1-4.

ClinicalTrial.gov, for NCT00731016, "Treatment of the Hutchinson-Gilford Progeria syndrome With a Combination of Pravastatin and Zoledronic Acid", Last update: Jul. 4, 2013, pp. 1-3.

ClinicalTrial.gov, for NCT00916747, "Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria", Last Update: Aug. 1, 2012, pp. 1-3.

Bénédicte Cantecor, et al., "Anti-Aging Efficacy of a New Alendronate-Pravastatin Cosmetic Combination: A Randomized Double Blind Comparative Study", *Journal of Cosmetics, Dermatological Sciences and Applications*, Sep. 2013, 3, 163-71.

Mallon, Patrick, et al., "Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men—a randomized, placebo-controlled study", *AIDS* (London, Eng), vol. 20, No. 7, Apr. 24, 2006, pp. 1003-1010.

Brown, Todd, "Selected Endocrine Topics in HIV; Osteoporosis and Adrenal Insufficiency", *The PRN Notebook* [online], vol. 12, Dec. 2007, pp. 1-9.

Baulch-Brown, et al., "Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma", *Leukemia Research*, New York, NY, US, vol. 31, No. 3, Jan. 12, 2007, pp. 341-352.

Varela, Ignacio, "Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging", *Nature Medicine*, Jul. 2008, No. 7, pp. 767-772.

Dayle McClintock, et al., "The Mutant Form of Lamin A that causes Hutchinson Gilford Progeria is a Biomarker of Cellular Aging in Human Skin", *PLoS ONE*, Dec. 2007, Issue 12, e1269, pp. 1-10.

Samuel Varghese, et al., "Alendronate Stimulates Collagenase 3 Expression in Osteoblasts by Posttranscriptional Mechanisms", *Journal of Bone and Mineral Research*, 15(12): 2345-2351.

H. Valleala, et al., "Regulation of MMP-9 (gelatinase B) in activated Human Monocyte/Macrophages by Two Different Types of Bisphosphonates", *Life Sciences*, 73: 2413-2420 (2003).

Basso, et al., "Farnesyl Transferase Inhibitors", *Journal of Lipid Research*, 2006, pp. 15-31, vol. 47.

Biamonti, et al., "The Gene for a Novel Human Lamin Maps at a Highly Transcribed Locus of Chromosome 19 which Replicates at the Onset of S-phase", *Molecular and Cellular Biology*, 1992, pp. 3499-3506, vol. 12.